Tevogen Inc. Reports $5.8 Million Net Loss for Q2 2026, Cash Position Improves

Tevogen Inc. reported a net loss of $5.8 million for the three months ended June 30, 2026, compared to a loss of $5.5 million for the same period in 2025. For the six months ended June 30, 2026, the company recorded a net loss of $11.2 million, a decrease from $15.9 million in the prior year. The reduction in losses is attributed to a significant decrease in general and administrative expenses, which fell to $4.6 million from $9.9 million year-over-year, primarily due to lower legal and professional fees and stock-based compensation. Research and development expenses increased to $6.4 million for the six-month period, up from $5.9 million, driven by higher stock-based compensation costs.

Tevogen's total operating expenses for the second quarter of 2026 were $5.7 million, slightly higher than the $5.4 million reported in the same quarter of 2025. The company’s cash position improved, with cash at the end of June 2026 totaling $1.1 million, up from $0.6 million at the end of 2025. This increase was supported by financing activities, including $3.0 million from the sale of pre-funded warrants and $2.0 million drawn from a loan agreement. The company has a remaining commitment of $7.0 million in grant funding from KRHP, which is expected to support ongoing operational expenses.

Strategically, Tevogen has made significant advancements in its product development pipeline, particularly with its precision T cell therapy, TVGN 489, which has completed a Phase 1 proof-of-concept trial for treating high-risk adult COVID-19 patients. The company is also leveraging artificial intelligence through its Tevogen.AI initiative to enhance drug development processes. Additionally, Tevogen has established a new healthcare services initiative aimed at improving healthcare affordability and accessibility.

As of June 30, 2026, Tevogen had 4,255,107 shares of common stock outstanding, following a reverse stock split effective March 6, 2026. The company continues to explore various funding strategies, including potential public offerings and partnerships, to support its ongoing research and development efforts. Management believes that the current cash balance, combined with available financing options, will provide sufficient resources to operate for at least the next 12 months. However, the company does not plan to initiate further clinical trials until additional funding is secured.